This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA to Report on Safety Monitoring of Recently Approved Drugs, Biologics
Patients, Docs Could Benefit From Release of Postmarketing Surveillance Info
By News Staff
The FDA said in a June 15 news release that summaries are based on reports by manufacturers, physicians and other health care providers, consumers, and others to the agency's Adverse Event Reporting System and the Vaccine Adverse Event Reporting System maintained by the FDA and the CDC. Summaries also are based on periodic safety information submitted to the FDA by manufacturers, information contained in the medical literature, and data from ongoing studies on approved drugs and biologics.
In addition to identifying adverse events associated with approved products, the FDA summaries will include information about steps the agency is taking to address safety issues.
According to FDA officials, some side effects may not become apparent until after a product has been approved and becomes available to a population larger and more diverse than the patients who participated in clinical trials that supported approval. Postmarket summaries may include information on potentially serious and previously unidentified risks, as well as known adverse events that occur more often than they did during clinical studies
Robert Ball, M.D., M.P.H., Sc.M., director of the Office of Biostatistics and Epidemiology in the FDA's Center for Biologics Evaluation and Research, said in the June 15 news release that the summaries will provide "clear and useful information in a timely manner that can be used by physicians and patients to make informed decisions."
The FDA said the first reports to be posted will contain information on drugs and biologics approved since September 2007, including several drugs for infections, hypertension, depression and other conditions.
FDA Proposals Would Shed Light on Drug Approval Process
Agency Seeking Public Input on Transparency Issues
FDA: Postmarketing Drug Safety Evaluations
FDA: Postmarket Drug Safety Information for Patients and Providers
Q&A on FDA's Postmarketing Safety Summaries of Recently Approved Drugs and Biologics